We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Annual Growth of POC Tests Forecast at Six Percent

By LabMedica International staff writers
Posted on 24 Dec 2012
Print article
The USD 16.7 billion market for point of care (POC) testing is expected to grow at the rate of 6 percent a year, slightly higher than the in vitro diagnostics market as a whole. In the late 1990s, the POC diagnostic market was expected to grow at a rate of 15% to 20% per year. While it has grown and is now a significant segment of the overall in vitro diagnostic (IVD) market, the rapid growth rates originally expected were not achieved.

POC testing includes in vitro diagnostic (IVD) tests performed by the patients themselves, such as glucose monitoring, pregnancy tests, and cholesterol tests, as well as tests performed at physicians’ offices, clinics and other patient care centers. Kalorama's analysis does not include tests sent to a central laboratory for processing. Much of the POC testing is carried out for glucose monitoring although in some cases coagulation and infectious disease testing can also be performed at the POC.

A Kalorama Information (New York, NY, USA) report authored by Sannes & Associates indicated that, “Growth in POC testing is being fueled by chronic diseases, the globalization of infectious diseases, and the associated public health issues. Advances in therapies are giving physicians more tools for the treatment of patients if they are able to rapidly diagnose the problem, which is helping to make the case for POC test purchases and investment in companies that provide them.”

The report contains a detailed segment breakdown of revenues, profiles of companies in the market, and a discussion of trends. New POC innovations are also detailed in the report.

The Kalorama report lists 140 companies that currently market POC tests, plus over 40 companies that are developing POC technologies and products. Companies profiled in the report use a wide range of different technologies to develop and market rapid tests for use at POC. These include a large number of IVD tests that are performed today only in centralized laboratories.

Related Links:

Kalorama Information


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Malaria Rapid Test
OnSite Malaria Pf/Pan Ag Rapid Test
New
Vitamin B12 Test
CHORUS CLIA VIT B12

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.